Cyclo Therapeutics, Inc.
CYTH · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $1,076 | $1,376 | $1,586 | $903 |
| % Growth | -21.8% | -13.2% | 75.5% | – |
| Cost of Goods Sold | $98 | $139 | $156 | $66 |
| Gross Profit | $978 | $1,237 | $1,430 | $837 |
| % Margin | 90.9% | 89.9% | 90.2% | 92.7% |
| R&D Expenses | $14,182 | $9,000 | $9,154 | $6,096 |
| G&A Expenses | $5,662 | $7,805 | $6,498 | $3,676 |
| SG&A Expenses | $5,666 | $7,818 | $6,516 | $3,681 |
| Sales & Mktg Exp. | $4 | $13 | $18 | $5 |
| Other Operating Expenses | $0 | $31 | $28 | $20 |
| Operating Expenses | $21,035 | $16,848 | $15,698 | $9,797 |
| Operating Income | -$20,050 | -$15,612 | -$14,268 | -$8,960 |
| % Margin | -1,862.7% | -1,134.8% | -899.8% | -991.8% |
| Other Income/Exp. Net | -$7 | $171 | $3 | $20 |
| Pre-Tax Income | -$20,057 | -$15,451 | -$14,287 | -$8,942 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$20,057 | -$15,280 | -$14,305 | -$8,923 |
| % Margin | -1,863.4% | -1,110.7% | -902.1% | -987.7% |
| EPS | -1.23 | -1.81 | -2.25 | -5.58 |
| % Growth | 32% | 19.6% | 59.7% | – |
| EPS Diluted | -1.23 | -1.81 | -2.25 | -5.58 |
| Weighted Avg Shares Out | 16,330 | 8,439 | 6,370 | 1,599 |
| Weighted Avg Shares Out Dil | 16,330 | 8,439 | 6,370 | 1,599 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $12 | $3 | $20 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $19 | $19 | $17 | $13 |
| EBITDA | -$20,031 | -$15,602 | -$14,270 | -$8,949 |
| % Margin | -1,860.9% | -1,134.1% | -899.9% | -990.6% |